How many insider trades does FilingIQ track for AVTX?

FilingIQ tracks 169 Form 4 insider transactions for AVTX (Avalo Therapeutics, Inc.), covering filings from Sep 15, 2021 onwards. 75 of those were filed in the last 90 days.

Are AVTX insiders net buyers or net sellers?

Across the full Form 4 history for AVTX, 68 transactions (40%) were open-market purchases and 31 (18%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does AVTX insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is AVTX in?

Avalo Therapeutics, Inc. (AVTX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $266.21M.

AVTX insider trading

Healthcare

Avalo Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

169

Last 90 days

Buys / sells

40% / 18%

Market cap

$266.21M

About Avalo Therapeutics, Inc.

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Company website: www.avalotx.com

AVTX insider activity at a glance

FilingIQ has scored 169 insider transactions for AVTX since Sep 15, 2021. The most recent filing in our index is dated May 7, 2026.

Across the full history, 68 open-market purchases and 31 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on AVTX insider trades is 57.5/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live AVTX trades on FilingIQ Raw filings on SEC EDGAR

Latest AVTX Form 4 filings

Armistice Capital Master Fund Ltd.

S Jun 26, 2023

NEIL GARRY ARTHUR CEO and Chairman of the Board

P Jun 9, 2023

Sullivan Christopher Ryan Chief Financial Officer

P Jun 9, 2023

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for AVTX?: FilingIQ tracks 169 Form 4 insider transactions for AVTX (Avalo Therapeutics, Inc.), covering filings from Sep 15, 2021 onwards. 75 of those were filed in the last 90 days.
Are AVTX insiders net buyers or net sellers?: Across the full Form 4 history for AVTX, 68 transactions (40%) were open-market purchases and 31 (18%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does AVTX insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is AVTX in?: Avalo Therapeutics, Inc. (AVTX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $266.21M.

Methodology & sources

Every AVTX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.